Research progress on mechanism of CD147 in promoting progression of breast cancer and related diagnosis and treatment_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LIU Jinting , WANG Rong ,  HUANG Jianjun

Department of Breast Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, P. R. China;

Corresponding author：

HUANG Jianjun, Email: h18985166863@163.com

Keywords：

breast cancer; CD147; active mechanism; progression; review

DOI：

10.7507/1007-9424.202011095

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the mechanism of CD147 in breast cancer invasion and metastasis, treatment, and drug resistance so as to provide reference for clinical decision-making.Method The relevant literatures about studies of CD147 in breast cancer in recent years were reviewed.Results CD147 was widely distributed in vivo and highly expressed in malignant tumor tissues. CD147 promoted matrix metalloproteinases and vascular endothelial growth factor productions and tumor microenvironment generation by extracellular matrix in breast cancer through different mechanisms. It degraded extracellular matrix and stimulated neovascularization to promote tumor invasion and metastasis. Related studies had shown that CD147 was highly expressed in the breast cancer tissues and which was associated with tumor grade and prognosis in patients with breast cancer, and it was a biological marker for diagnosis of breast cancer. However, a large of drugs targeted for CD147 and its involved pathways didn’t well benefit patient with breast cancer due to the failure of clinical trials and chemotherapy resistance.Conclusions CD147 plays a key role in development, invasion and metastasis, diagnosis and treatment, and drug resistance of breast cancer, as well as guiding the treatment and prognosis of patients. However, benefits are poor, and relevant molecular mechanisms of action are limited.

Citation： LIU Jinting, WANG Rong, HUANG Jianjun. Research progress on mechanism of CD147 in promoting progression of breast cancer and related diagnosis and treatment. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(10): 1372-1377. doi: 10.7507/1007-9424.202011095 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021 Feb 4. Online ahead of print.
3.	陈万青, 李贺, 孙可欣, 等. 2014 年中国恶性肿瘤发病和死亡分析. 中华肿瘤杂志, 2018, 40(1): 5-13.
4.	Xin X, Zeng X, Gu H, et al. CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis. Sci Rep, 2016, 6: 32804.
5.	Wu B, Cui J, Yang XM, et al. Cytoplasmic fragment of CD147 generated by regulated intramembrane proteolysis contributes to HCC by promoting autophagy. Cell Death Dis, 2017, 8(7): e2925.
6.	Muramatsu T. Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners. J Biochem, 2016, 159(5): 481-490.
7.	Guo H, Majmudar G, Jensen TC, et al. Characterization of the gene for human EMMPRIN, a tumor cell surface inducer of matrix metalloproteinases. Gene, 1998, 220(1-2): 99-108.
8.	Weidle UH, Scheuer W, Eggle D, et al. Cancer-related issues of CD147. Cancer Genomics Proteomics, 2010, 7(3): 157-169.
9.	李浩, 游潮. CD147/EMMPRIN 与脑胶质瘤关系的研究进展. 华西医学, 2005, 20(2): 376-377.
10.	杨捷, 周晴, 徐小勇, 等. CD147 与肝癌关系的研究进展. 中国普外基础与临床杂志, 2015, 22(10): 1279-1283.
11.	唐小乔, 桑剑锋, 张寅, 等. CD147 在乳腺癌细胞中的表达及对癌细胞增殖及 TGF-β 信号通路的影响. 肿瘤学杂志, 2020, 26(5): 413-417.
12.	Cierna Z, Mego M, Janega P, et al. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. BMC Cancer, 2014, 14(1): 472.
13.	Wang J, Ye C, Lu D, et al. Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis. Oncotarget, 2017, 8(53): 91379-91390.
14.	Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature, 2007, 446(7137): 765-770.
15.	Kessenbrock K, Dijkgraaf GJ, Lawson DA, et al. A role for matrix metalloproteinases in regulating mammary stem cell function via the Wnt signaling pathway. Cell Stem Cell, 2013, 13(3): 300-313.
16.	Chou AK, Hsiao CL, Shih TC, et al. The contribution of matrix metalloproteinase-7 promoter genotypes in breast cancer in Taiwan. Anticancer Res, 2017, 37(9): 4973-4977.
17.	Sizemore ST, Sizemore GM, Booth CN, et al. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. Breast Cancer Res Treat, 2014, 146(1): 25-40.
18.	Alaseem A, Alhazzani K, Dondapati P, et al. Matrix metalloproteinases: A challenging paradigm of cancer management. Semin Cancer Biol, 2019, 56: 100-115.
19.	Eiró N, Fernandez-Garcia B, Vázquez J, et al. A phenotype from tumor stroma based on the expression of metalloproteases and their inhibitors, associated with prognosis in breast cancer. Oncoimmunology, 2015, 4(7): e992222.
20.	Knutti N, Huber O, Friedrich K. CD147 (EMMPRIN) controls malignant properties of breast cancer cells by interdependent signaling of Wnt and JAK/STAT pathways. Mol Cell Biochem, 2019, 451(1-2): 197-209.
21.	Young D, Das N, Anowai A, et al. Matrix metalloproteases as influencers of the cells’ social media. Int J Mol Sci, 2019, 20(16): 3847.
22.	Tang Y, Nakada MT, Rafferty P, et al. Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res, 2006, 4(6): 371-377.
23.	Qiao S, Liu C, Xu W, et al. Up-regulated expression of CD147 gene in malignant bone tumor and the possible induction mechanism during osteoclast formation. Braz J Med Biol Res, 2018, 51(9): e6948.
24.	Guindolet D, Gabison EE. Role of CD147 (EMMPRIN/Basigin) in tissue remodeling. Anat Rec (Hoboken), 2020, 303(6): 1584-1589.
25.	Wang C, Xu C, Niu R, et al. MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147. BMC Cancer, 2019, 19(1): 577.
26.	Grass GD, Toole BP. How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity. Biosci Rep, 2015, 36(1): e00283.
27.	Wu J, Hao ZW, Zhao YX, et al. Full-length soluble CD147 promotes MMP-2 expression and is a potential serological marker in detection of hepatocellular carcinoma. J Transl Med, 2014, 12: 190.
28.	Zhang W, Liu L, Su H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer, 2019, 121(10): 837-845.
29.	Taylor PM, Woodfield RJ, Hodgkin MN, et al. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene, 2002, 21(37): 5765-5772.
30.	Aoki M, Koga K, Miyazaki M, et al. CD73 complexes with emmprin to regulate MMP-2 production from co-cultured sarcoma cells and fibroblasts. BMC Cancer, 2019, 19(1): 912.
31.	Conlon GA, Murray GI. Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol, 2019, 247(5): 629-640.
32.	Yang S, Qi F, Tang C, et al. CD147 promotes the proliferation, invasiveness, migration and angiogenesis of human lung carcinoma cells. Oncol Lett, 2017, 13(2): 898-904.
33.	Martin MD, Carter KJ, Jean-Philippe SR, et al. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res, 2008, 68(15): 6251-6259.
34.	Marieb EA, Zoltan-Jones A, Li R, et al. Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res, 2004, 64(4): 1229-1232.
35.	Hu L, Hofmann J, Jaffe RB. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin Cancer Res, 2005, 11(22): 8208-8212.
36.	Wang L, Feng Y, Xie X, et al. Neuropilin-1 aggravates liver cirrhosis by promoting angiogenesis via VEGFR2-dependent PI3K/Akt pathway in hepatic sinusoidal endothelial cells. EBioMedicine, 2019, 43: 525-536.
37.	Manou D, Caon I, Bouris P, et al. The complex interplay between extracellular matrix and cells in tissues. Methods Mol Biol, 2019, 1952: 1-20.
38.	Xiang T, Xia X, Yan W. Expression of matrix metalloproteinases-2/-9 is associated with microvessel density in pancreatic cancer. Am J Ther, 2017, 24(4): e431-e434.
39.	Roskoski R. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacol Res, 2017, 120: 116-132.
40.	Huang Q, Li J, Xing J, et al. CD147 promotes reprogramming of glucose metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway. J Hepatol, 2014, 61(4): 859-866.
41.	Slomiany MG, Grass GD, Robertson AD, et al. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res, 2009, 69(4): 1293-1301.
42.	Toole BP. The CD147-HYALURONAN axis in cancer. Anat Rec (Hoboken), 2020, 303(6): 1573-1583.
43.	Singh S, Chakrabarti R. Consequences of EMT-driven changes in the immune microenvironment of breast cancer and therapeutic response of cancer cells. J Clin Med, 2019, 8(5): 642.
44.	Kuang Y, Wang S, Tang L, et al. Cluster of differentiation 147 mediates chemoresistance in breast cancer by affecting vacuolar H⁺-ATPase expression and activity. Oncol Lett, 2018, 15(5): 7279-7290.
45.	Panich T, Tragoolpua K, Pata S, et al. Downregulation of extracellular matrix metalloproteinase inducer by scFv-M6-1B9 intrabody suppresses cervical cancer invasion through inhibition of urokinase-type plasminogen activator. Cancer Biother Radiopharm, 2017, 32(1): 1-8.
46.	Yong YL, Liao CG, Wei D, et al. CD147 overexpression promotes tumorigenicity in Chinese hamster ovary cells. Cell Biol Int, 2016, 40(4): 375-386.
47.	Hatanaka M, Higashi Y, Kawai K, et al. CD147-targeted siRNA in A375 malignant melanoma cells induces the phosphorylation of EGFR and downregulates cdc25C and MEK phosphorylation. Oncol Lett, 2016, 1(4): 2424-2428.
48.	梦遥, 陈志南. CD147 促进失巢诱导的乳腺癌细胞重编程. 西安: 第四军医大学, 2016.
49.	Lv YG, Wang T, Fan J, et al. The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147⁺ breast cancer stem cells. Tumour Biol, 2017, 39(4): 1010428317695927.
50.	Kong LM, Liao CG, Fei F, et al. Transcription factor Sp1 regulates expression of cancer-associated molecule CD147 in human lung cancer. Cancer Sci, 2010, 101(6): 1463-1470.
51.	Menashi S, Serova M, Ma L, et al. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res, 2003, 63(22): 7575-7580.
52.	Xu JW, Li QQ, Tao LL, et al. Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells. Int J Oncol, 2011, 39(6): 1501-1509.
53.	Li QQ, Wang WJ, Xu JD, et al. Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci, 2007, 98(7): 1064-1069.
54.	Grass GD, Dai L, Qin Z, et al. CD147: regulator of hyaluronan signaling in invasiveness and chemoresistance. Adv Cancer Res, 2014, 123: 351-373.
55.	Zhou S, Liao L, Chen C, et al. CD147 mediates chemoresistance in breast cancer via ABCG2 by affecting its cellular localization and dimerization. Cancer Lett, 2013, 337(2): 285-292.
56.	Zhao S, Chen C, Liu S, et al. CD147 promotes MTX resistance by immune cells through up-regulating ABCG2 expression and function. J Dermatol Sci, 2013, 70(3): 182-189.
57.	Yan L, Zucker S, Toole BP. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost, 2005, 93(2): 199-204.
58.	Spugnini EP, Buglioni S, Carocci F, et al. High dose lansoprazole combined with metronomic chemotherapy: a phase Ⅰ/Ⅱ study in companion animals with spontaneously occurring tumors. J Transl Med, 2014, 12: 225.
59.	Xiong L, Ding L, Ning H, et al. CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells. Oncotarget, 2016, 7(36): 57737-57751.
60.	Wu L, Sun B, Lin X, et al. I¹³¹ reinforces antitumor activity of metuximab by reversing epithelial-mesenchymal transition via VEGFR-2 signaling in hepatocellular carcinoma. Genes Cells, 2018, 23(1): 35-45.
61.	Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med, 2009, 360(7): 679-691.
62.	Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res, 2009, 69(4): 1517-1526.
63.	Brkic M, Balusu S, Libert C, et al. Friends or foes: Matrix metalloproteinases and their multifaceted roles in neurodegenerative diseases. Mediators Inflamm, 2015, 2015: 620581.
64.	Han B, Peng X, Cheng D, et al. Delphinidin suppresses breast carcinogenesis through the HOTAIR/microRNA-34a axis. Cancer Sci, 2019, 110(10): 3089-3097.
65.	Marturano A, Hendrickx MLV, Falcinelli E, et al. Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools. Nanomedicine, 2020, 24: 102103.
66.	Luz MC, Perez MM, Azzalis LA, et al. Evaluation of MCT1, MCT4 and CD147 genes in peripheral blood cells of breast cancer patients and their potential use as diagnostic and prognostic markers. Int J Mol Sci, 2017, 18(4): 170.
67.	Kuang YH, Liu YJ, Tang LL, et al. Plasma soluble cluster of differentiation 147 levels are increased in breast cancer patients and associated with lymph node metastasis and chemoresistance. Hong Kong Med J, 2018, 24(3): 252-260.
68.	周晟, 刘聪, 吴时敏, 等. CD147 和 MMP-2 在乳腺癌组织中的表达及其与预后的相关性. 癌症, 2005, 24(7): 874-879.
69.	Liu M, Tsang JYS, Lee M, et al. CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer. J Clin Pathol, 2018, 71(11): 1007-1014.
70.	Fan H, Yi W, Wang C, et al. The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies. Oncotarget, 2017, 8(47): 82643-82660.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021 Feb 4. Online ahead of print.
3. 陈万青, 李贺, 孙可欣, 等. 2014 年中国恶性肿瘤发病和死亡分析. 中华肿瘤杂志, 2018, 40(1): 5-13.
4. Xin X, Zeng X, Gu H, et al. CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis. Sci Rep, 2016, 6: 32804.
5. Wu B, Cui J, Yang XM, et al. Cytoplasmic fragment of CD147 generated by regulated intramembrane proteolysis contributes to HCC by promoting autophagy. Cell Death Dis, 2017, 8(7): e2925.
6. Muramatsu T. Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners. J Biochem, 2016, 159(5): 481-490.
7. Guo H, Majmudar G, Jensen TC, et al. Characterization of the gene for human EMMPRIN, a tumor cell surface inducer of matrix metalloproteinases. Gene, 1998, 220(1-2): 99-108.
8. Weidle UH, Scheuer W, Eggle D, et al. Cancer-related issues of CD147. Cancer Genomics Proteomics, 2010, 7(3): 157-169.
9. 李浩, 游潮. CD147/EMMPRIN 与脑胶质瘤关系的研究进展. 华西医学, 2005, 20(2): 376-377.
10. 杨捷, 周晴, 徐小勇, 等. CD147 与肝癌关系的研究进展. 中国普外基础与临床杂志, 2015, 22(10): 1279-1283.
11. 唐小乔, 桑剑锋, 张寅, 等. CD147 在乳腺癌细胞中的表达及对癌细胞增殖及 TGF-β 信号通路的影响. 肿瘤学杂志, 2020, 26(5): 413-417.
12. Cierna Z, Mego M, Janega P, et al. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. BMC Cancer, 2014, 14(1): 472.
13. Wang J, Ye C, Lu D, et al. Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis. Oncotarget, 2017, 8(53): 91379-91390.
14. Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature, 2007, 446(7137): 765-770.
15. Kessenbrock K, Dijkgraaf GJ, Lawson DA, et al. A role for matrix metalloproteinases in regulating mammary stem cell function via the Wnt signaling pathway. Cell Stem Cell, 2013, 13(3): 300-313.
16. Chou AK, Hsiao CL, Shih TC, et al. The contribution of matrix metalloproteinase-7 promoter genotypes in breast cancer in Taiwan. Anticancer Res, 2017, 37(9): 4973-4977.
17. Sizemore ST, Sizemore GM, Booth CN, et al. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. Breast Cancer Res Treat, 2014, 146(1): 25-40.
18. Alaseem A, Alhazzani K, Dondapati P, et al. Matrix metalloproteinases: A challenging paradigm of cancer management. Semin Cancer Biol, 2019, 56: 100-115.
19. Eiró N, Fernandez-Garcia B, Vázquez J, et al. A phenotype from tumor stroma based on the expression of metalloproteases and their inhibitors, associated with prognosis in breast cancer. Oncoimmunology, 2015, 4(7): e992222.
20. Knutti N, Huber O, Friedrich K. CD147 (EMMPRIN) controls malignant properties of breast cancer cells by interdependent signaling of Wnt and JAK/STAT pathways. Mol Cell Biochem, 2019, 451(1-2): 197-209.
21. Young D, Das N, Anowai A, et al. Matrix metalloproteases as influencers of the cells’ social media. Int J Mol Sci, 2019, 20(16): 3847.
22. Tang Y, Nakada MT, Rafferty P, et al. Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res, 2006, 4(6): 371-377.
23. Qiao S, Liu C, Xu W, et al. Up-regulated expression of CD147 gene in malignant bone tumor and the possible induction mechanism during osteoclast formation. Braz J Med Biol Res, 2018, 51(9): e6948.
24. Guindolet D, Gabison EE. Role of CD147 (EMMPRIN/Basigin) in tissue remodeling. Anat Rec (Hoboken), 2020, 303(6): 1584-1589.
25. Wang C, Xu C, Niu R, et al. MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147. BMC Cancer, 2019, 19(1): 577.
26. Grass GD, Toole BP. How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity. Biosci Rep, 2015, 36(1): e00283.
27. Wu J, Hao ZW, Zhao YX, et al. Full-length soluble CD147 promotes MMP-2 expression and is a potential serological marker in detection of hepatocellular carcinoma. J Transl Med, 2014, 12: 190.
28. Zhang W, Liu L, Su H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer, 2019, 121(10): 837-845.
29. Taylor PM, Woodfield RJ, Hodgkin MN, et al. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene, 2002, 21(37): 5765-5772.
30. Aoki M, Koga K, Miyazaki M, et al. CD73 complexes with emmprin to regulate MMP-2 production from co-cultured sarcoma cells and fibroblasts. BMC Cancer, 2019, 19(1): 912.
31. Conlon GA, Murray GI. Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol, 2019, 247(5): 629-640.
32. Yang S, Qi F, Tang C, et al. CD147 promotes the proliferation, invasiveness, migration and angiogenesis of human lung carcinoma cells. Oncol Lett, 2017, 13(2): 898-904.
33. Martin MD, Carter KJ, Jean-Philippe SR, et al. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res, 2008, 68(15): 6251-6259.
34. Marieb EA, Zoltan-Jones A, Li R, et al. Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res, 2004, 64(4): 1229-1232.
35. Hu L, Hofmann J, Jaffe RB. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin Cancer Res, 2005, 11(22): 8208-8212.
36. Wang L, Feng Y, Xie X, et al. Neuropilin-1 aggravates liver cirrhosis by promoting angiogenesis via VEGFR2-dependent PI3K/Akt pathway in hepatic sinusoidal endothelial cells. EBioMedicine, 2019, 43: 525-536.
37. Manou D, Caon I, Bouris P, et al. The complex interplay between extracellular matrix and cells in tissues. Methods Mol Biol, 2019, 1952: 1-20.
38. Xiang T, Xia X, Yan W. Expression of matrix metalloproteinases-2/-9 is associated with microvessel density in pancreatic cancer. Am J Ther, 2017, 24(4): e431-e434.
39. Roskoski R. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacol Res, 2017, 120: 116-132.
40. Huang Q, Li J, Xing J, et al. CD147 promotes reprogramming of glucose metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway. J Hepatol, 2014, 61(4): 859-866.
41. Slomiany MG, Grass GD, Robertson AD, et al. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res, 2009, 69(4): 1293-1301.
42. Toole BP. The CD147-HYALURONAN axis in cancer. Anat Rec (Hoboken), 2020, 303(6): 1573-1583.
43. Singh S, Chakrabarti R. Consequences of EMT-driven changes in the immune microenvironment of breast cancer and therapeutic response of cancer cells. J Clin Med, 2019, 8(5): 642.
44. Kuang Y, Wang S, Tang L, et al. Cluster of differentiation 147 mediates chemoresistance in breast cancer by affecting vacuolar H⁺-ATPase expression and activity. Oncol Lett, 2018, 15(5): 7279-7290.
45. Panich T, Tragoolpua K, Pata S, et al. Downregulation of extracellular matrix metalloproteinase inducer by scFv-M6-1B9 intrabody suppresses cervical cancer invasion through inhibition of urokinase-type plasminogen activator. Cancer Biother Radiopharm, 2017, 32(1): 1-8.
46. Yong YL, Liao CG, Wei D, et al. CD147 overexpression promotes tumorigenicity in Chinese hamster ovary cells. Cell Biol Int, 2016, 40(4): 375-386.
47. Hatanaka M, Higashi Y, Kawai K, et al. CD147-targeted siRNA in A375 malignant melanoma cells induces the phosphorylation of EGFR and downregulates cdc25C and MEK phosphorylation. Oncol Lett, 2016, 1(4): 2424-2428.
48. 梦遥, 陈志南. CD147 促进失巢诱导的乳腺癌细胞重编程. 西安: 第四军医大学, 2016.
49. Lv YG, Wang T, Fan J, et al. The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147⁺ breast cancer stem cells. Tumour Biol, 2017, 39(4): 1010428317695927.
50. Kong LM, Liao CG, Fei F, et al. Transcription factor Sp1 regulates expression of cancer-associated molecule CD147 in human lung cancer. Cancer Sci, 2010, 101(6): 1463-1470.
51. Menashi S, Serova M, Ma L, et al. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res, 2003, 63(22): 7575-7580.
52. Xu JW, Li QQ, Tao LL, et al. Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells. Int J Oncol, 2011, 39(6): 1501-1509.
53. Li QQ, Wang WJ, Xu JD, et al. Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci, 2007, 98(7): 1064-1069.
54. Grass GD, Dai L, Qin Z, et al. CD147: regulator of hyaluronan signaling in invasiveness and chemoresistance. Adv Cancer Res, 2014, 123: 351-373.
55. Zhou S, Liao L, Chen C, et al. CD147 mediates chemoresistance in breast cancer via ABCG2 by affecting its cellular localization and dimerization. Cancer Lett, 2013, 337(2): 285-292.
56. Zhao S, Chen C, Liu S, et al. CD147 promotes MTX resistance by immune cells through up-regulating ABCG2 expression and function. J Dermatol Sci, 2013, 70(3): 182-189.
57. Yan L, Zucker S, Toole BP. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost, 2005, 93(2): 199-204.
58. Spugnini EP, Buglioni S, Carocci F, et al. High dose lansoprazole combined with metronomic chemotherapy: a phase Ⅰ/Ⅱ study in companion animals with spontaneously occurring tumors. J Transl Med, 2014, 12: 225.
59. Xiong L, Ding L, Ning H, et al. CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells. Oncotarget, 2016, 7(36): 57737-57751.
60. Wu L, Sun B, Lin X, et al. I¹³¹ reinforces antitumor activity of metuximab by reversing epithelial-mesenchymal transition via VEGFR-2 signaling in hepatocellular carcinoma. Genes Cells, 2018, 23(1): 35-45.
61. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med, 2009, 360(7): 679-691.
62. Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res, 2009, 69(4): 1517-1526.
63. Brkic M, Balusu S, Libert C, et al. Friends or foes: Matrix metalloproteinases and their multifaceted roles in neurodegenerative diseases. Mediators Inflamm, 2015, 2015: 620581.
64. Han B, Peng X, Cheng D, et al. Delphinidin suppresses breast carcinogenesis through the HOTAIR/microRNA-34a axis. Cancer Sci, 2019, 110(10): 3089-3097.
65. Marturano A, Hendrickx MLV, Falcinelli E, et al. Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools. Nanomedicine, 2020, 24: 102103.
66. Luz MC, Perez MM, Azzalis LA, et al. Evaluation of MCT1, MCT4 and CD147 genes in peripheral blood cells of breast cancer patients and their potential use as diagnostic and prognostic markers. Int J Mol Sci, 2017, 18(4): 170.
67. Kuang YH, Liu YJ, Tang LL, et al. Plasma soluble cluster of differentiation 147 levels are increased in breast cancer patients and associated with lymph node metastasis and chemoresistance. Hong Kong Med J, 2018, 24(3): 252-260.
68. 周晟, 刘聪, 吴时敏, 等. CD147 和 MMP-2 在乳腺癌组织中的表达及其与预后的相关性. 癌症, 2005, 24(7): 874-879.
69. Liu M, Tsang JYS, Lee M, et al. CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer. J Clin Pathol, 2018, 71(11): 1007-1014.
70. Fan H, Yi W, Wang C, et al. The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies. Oncotarget, 2017, 8(47): 82643-82660.

Previous Article
Advancement of mesenchymal stem cells in relieving acute pancreatitis
Next Article
Research progress on the pathogenesis of ischemic bile duct injury after liver TACE

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress on mechanism of CD147 in promoting progression of breast cancer and related diagnosis and treatment

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content